Jean George, Lightstone Ventures

Portrait

Jean George is a general partner of Lightstone Ventures. She focuses on biopharmaceutical and medical device investments out of the firm’s Boston office, where she also serves as a general partner of Advanced Technology Ventures.

Her representative investments include Acceleron Pharma, Calithera Biosciences, Catabasis Pharmaceuticals, Flex Pharma, Five Prime Therapeutics, Hydra Biosciences, Hypnion (acquired by Eli Lilly), Portola Pharmaceuticals, Proteolix (acquired by Onyx Pharmaceuticals), Thrasos Therapeutics, Tizona Therapetics, Verastem and Zeltiq Aesthetics.

Jean has been featured on the Forbes Midas List and was previously a member of the Scientific Advisory Board for the Massachusetts Life Sciences Center. She has been in the biopharmaceutical industry for over 20 years, including 10 years with Genzyme Corporation, where she held a variety of operational roles in marketing, product development, and business development, including Vice President of Global Sales and Marketing. She also was Vice President and Founder of Genzyme’s Tissue Repair Division.

Jean joined BancBoston Ventures in 1998 to lead its life sciences investments. There she led investments in Neurometrix, Ironwood Pharmaceuticals, NuGenesis Technologies (acquired by Waters), and Syntonix Pharmaceuticals (acquired by Biogen/Idec). Previously, Jean spent six years working in chemistry and bioresearch.

Carl L. Gordon, Ph.D., C.F.A, OrbiMed

Portrait

Carl L. Gordon is a founding partner and co-head of global private equity at OrbiMed.

He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995.

Carl received his doctorate in molecular biology from the Massachusetts Institute of Technology (1993) and his undergraduate degree from Harvard College (1987). Carl was included on the Forbes Midas List of top venture capital investors in 2014.

David Lubner, Independent Director

Portrait

David Lubner is an experienced financial professional with tenure in the biotech and pharmaceutical industry. He serves as executive vice president and chief financial officer of Ra Pharma, acquired by UCB in April 2020.

Prior to joining Ra Pharma, David served as a member of the senior management team of Tetraphase Pharmaceuticals, Inc. and PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company, which was acquired by IMS Health in 2015. In addition he served as a senior leader at ProScript, Inc., where Velcade® (bortezomib), a therapy widely used for treatment of the blood cancer multiple myeloma, was discovered. He currently serves on the board of Dyne Therapeutics and previously served on the Board of Directors of Nightstar Therapeutics plc (Nasdaq: NITE), a company focused on the development of one-time retinal gene therapies for patients suffering from rare inherited retinal diseases, which was acquired by Biogen in June 2019.

David is a Certified Public Accountant. He received his B.S. in business administration from Northeastern University and an M.S. in taxation from Bentley University.

Jason Meyenburg, MBA, Chief Executive Officer

Portrait

Jason Meyenburg is Chief Executive Officer at Gemini Therapeutics. He has more than 20 years of experience in developing and commercializing therapies for patients with serious conditions.

Prior to joining Gemini, Jason served as Chief Commercial Officer at Orchard Therapeutics, a company advancing gene therapies for rare diseases, where he was responsible for building out the global commercial operations. During his tenure at Orchard, the company acquired and integrated the gene therapy portfolio from GSK and launched an IPO of $200 million in 2019.

Before Orchard, Jason was Chief Commercial Officer of Vtesse Pharmaceuticals, a company developing a therapy for the rare disease Niemann-Pick C in collaboration with the NIH, and of Sucampo Pharmaceuticals through the acquisition of Vtesse. Before Vtesse and Sucampo, Jason spent 13 years at Alexion Pharmaceuticals in roles of increasing responsibility, including Executive Director Project Management & Japan Operations, Vice President Commercial Operations Northern/Eastern Europe and Middle East/Africa based in Switzerland, and Senior Vice President, Commercial Operations, The Americas.

Jason holds an MBA from Duke University and a B.S. in biochemistry from University of Maryland, College Park.

Tuyen Ong, MBA, M.D., Independent Board Member

Portrait

Dr. Ong is a board-certified ophthalmologist and biotechnology/pharmaceutical industry management executive. He currently serves as senior vice president and head of the ophthalmology franchise at Biogen.

Dr. Ong served as chief development officer at Nightstar Therapeutics up until its acquisition by Biogen in June 2019. During this time, he was involved with the company’s public listing on the NASDAQ, corporate and gene therapy strategy, and investor and M&A activities. Dr. Ong brings over 20 years of clinical and drug development experience from both large pharma and biotech, working in the fields of ophthalmology, genetic and rare disease at PTC Therapeutics Inc., Bausch and Lomb Inc. (acquired by Valeant Pharmaceuticals International, Inc.), and Pfizer.

Dr. Ong holds an M.D. from the University College London and an M.B.A. from New York University Stern School of Business. He is a member of the Royal College of Ophthalmologists and a Churchill Fellow.

Jason Rhodes, Atlas Venture

Portrait

Jason is a general partner with Atlas Venture, where he focuses on creating and building novel therapeutics companies. Jason is the chairman and was the founding CEO of Generation Bio (NASDAQ: GBIO) and Dyne Therapeutics (NASDAQ: DYN). He is on the boards of Replimune (NASDAQ: REPL), Gemini Therapeutics (NASDAQ: GMTX), Accent Therapeutics, and Be Biopharma and was previously the chairman and founding CEO of Disarm Therapeutics, acquired by Eli Lilly in 2020. Prior to Atlas, he held leadership positions with Epizyme (NASDAQ: EPZM) and Alnylam Pharmaceuticals (NASDAQ: ALNY) and was a founder and general partner with Fidelity Biosciences (now F-Prime Capital), the biotech venture capital arm of Fidelity Investments.

Jason received his B.A. from Yale University and his M.B.A. from the Wharton School of the University of Pennsylvania.

Jim Tananbaum, Foresite Capital

Portrait

Jim Tananbaum, MD ’89, MBA ’91, is the founder and chief executive officer of Foresite Capital, a U.S.-focused healthcare investment firm established in 2011 that has approximately $3 billion in assets under management. During the last three decades, Jim has been a thought partner for some of the most impactful and fastest growth companies of their generation, including 10x Genomics, Amerigroup, and Jazz Pharmaceuticals. A four-time Midas List honoree, he currently serves as a member of the Yale University Council and the advisory committee of Yale School of Engineering & Applied Science.

 

As an undergraduate, Jim attended Yale, where he graduated with a BS and BSEE in applied math and electrical engineering/computer science.  He then earned an MD from Harvard, graduating from the Harvard-MIT Program in Health Sciences and Technology (HST). He also earned an MBA from Harvard while playing rugby.